[Special Stock] Syntheca Bio, the World's Only Bio 'Supercomputer'... Reducing Drug Development from 7 Years to 2 Years

AI drug development specialist Syntekabio is showing strong performance. The news that it will officially launch the world's only bio supercomputer-based full-cycle AI drug development platform service, capable of everything from substance discovery to clinical management, appears to be influencing its stock price.

As of 1:45 PM on the 16th, Syntekabio is trading at 6,400 KRW, up 20.3% from the previous trading day.

Syntekabio introduced its full-cycle AI drug development platform as the world's only system where a supercomputer manages all processes of drug development.

The company explained that it aims to shorten the drug development process, which previously took 5 to 7 years before the IND (Investigational New Drug) application stage, to about 2 years, accelerating the speed of drug candidate discovery and substance optimization by 3 to 4 times.

The full-cycle AI drug development platform utilizes a language model generated based on three major databases: 200 million protein structure data from Google AlphaFold, 100 million protein-ligand 3D binding data from the Protein Data Bank (PDB), and a compound library of 10 billion molecules. Syntekabio completed its own language model using these three big data sources and developed a system that enables cloud-based searches in seconds. Unlike existing AI platforms, it has a system capable of infinite generation until effective substances (Hits) are discovered.

Syntekabio's 'STB-CLOUD' operates 25 slots, each consisting of 200 virtual CPU-GPUs. This allows simultaneous discovery of effective substances for 25 targets. Using this, searching through 10 billion compounds takes 3 hours, and in silico evaluation to determine substance efficacy takes 1 hour. Repeating a 4-hour cycle 200 times requires 800 hours, approximately one month.

A company representative said about the full-cycle AI drug development platform, "It is an all-encompassing AI platform and technology that includes molecular dynamics simulation, binding free energy calculation, and more, all gathered in one place for drug development." They added, "By operating cutting-edge technology in an automated environment with supercomputing infrastructure, drug developers can focus more on their core research objectives, free from complex operational burdens."

Syntekabio is conducting testing and evaluation on numerous extreme drug targets that are not searchable via language model-based methods. These drug targets include ▲ligand warhead discovery for targeted protein degradation (TPD), ▲AlphaFold 3D structures of many proteins whose structures have not been revealed, ▲targets in cell walls that are difficult to search, and ▲about ten targets requiring selective binding due to high similarity but differential expression depending on cell tissue and tissue type. Some have completed animal experiment verification and are preparing submissions to major journals.

Syntekabio CEO Jeong Jong-seon said, "The full-cycle AI drug development platform is an innovative technology that will transform the paradigm of drug development." He added, "We will open the way for scientists and developers who challenge the impossible to rapidly and efficiently develop innovative therapeutics that protect human health and life."